Depression news, articles and features | żěè¶ĚĘÓƵ /topic/depression/ Science news and science articles from żěè¶ĚĘÓƵ Fri, 01 May 2026 15:05:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 242057827 Why the keto diet could be a revolutionary way to treat mental illness /article/2523421-why-the-keto-diet-could-be-a-revolutionary-way-to-treat-mental-illness/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Mon, 27 Apr 2026 15:00:03 +0000 /?post_type=article&p=2523421 2523421 Psychedelics may be no better than antidepressants for depression /article/2519824-psychedelics-may-be-no-better-than-antidepressants-for-depression/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Wed, 18 Mar 2026 15:00:18 +0000 /?post_type=article&p=2519824 A scanning electron microscope image of spores from a type of magic mushroom
A scanning electron microscope image of spores from a type of magic mushroom
Ted Kinsman/SCIENCE PHOTO LIBRARY

Psychedelics may be no more effective than traditional antidepressants for treating depression. Drugs like psilocybin, LSD and DMT have shown huge promise recently in treating various mental health conditions, but an ongoing issue in such research is that people can often gauge whether they have received these drugs or a placebo, based on the former’s hallucinogenic effects. When this is accounted for, it seems that psychedelics can be effective for depression, but no more so than antidepressants are.

“Our results do not disprove the exciting results about psychedelic treatments,” says at the University of California, San Francisco (UCSF). “We also show that psychedelics are effective at treating depression; it is just that they are not more effective than open-label [unblinded] traditional antidepressants, which feels underwhelming given the attention [on psychedelics].”

Hallucinogens have shown promise for treating depression, anxiety and obsessive compulsive disorder. The gold standard for drug development is usually to test a treatment against a placebo. This overcomes the placebo effect, when someone’s medical symptoms are lessened through the power of suggestion and expectation. But in psychedelic research, people are often able to perceive whether they are in the dosing group.

To get around this, Szigeti and his colleagues have studied 24 trials, eight of which looked at psychedelic-assisted therapy (PAT) – the combined treatment of psychotherapy and psychedelics. The remaining 16 were open-label trials for traditional antidepressants. This means that both the researchers and the participants knew what treatment was being administered, eliminating the “blinding” that is also considered the gold standard in most trials.

The team found that the traditional antidepressants seemed to outperform PAT by just 0.3 points on a 52-point depression-rating scale, which is neither statistically nor clinically significant.

Psychedelics have generally outperformed a placebo by 7.3 points in previous trials, versus about 2.4 points when antidepressants are pitted against a placebo. But the researchers argue that much of this advantage may stem from participants being able to gauge whether they have received a psychedelic. “Ours and other studies provide emerging evidence that unblinding suppresses the placebo response,” says Szigeti.

“This is an intriguing review with a clever approach to addressing the placebo question in psychedelic trials for depression,” says at John Hopkins University in Maryland, who was involved in some of the studies the team reviewed. Some researchers have a “a religious-like zeal to show psychedelics are effective, rather than a principled approach of trying to really test hypotheses”, he says.

But at Imperial College London says psychedelics need to be compared head-to-head against antidepressants, not just placebos, to understand their effects: “The jury is still out scientifically.” Only one trial has done so, , a selective serotonin reuptake inhibitor antidepressant – and it found no significant difference for easing depression.

, also at UCSF – who was involved in the escitalopram trial – has a common criticism of the methodology behind the latest study: that comparing multiple trials with different designs, including varying sample sizes and inclusion criteria, doesn’t generally yield a conclusive result. “It’s proposed as comparing apples with apples, when really it’s more like comparing apples with oranges,” he says.

Last September, a study looking at LSD for treating anxiety sought to decrease the likelihood of unblinding by giving lower doses of the drug to the control group, so they induced hallucinogenic effects without necessarily impacting mental health. And , people were given a sedative that can cause amnesia to erase their memory of the trip.

Journal reference:

JAMA Psychiatry

]]>
2519824
Why some people cannot move on from the death of a loved one /article/2515929-why-some-people-cannot-move-on-from-the-death-of-a-loved-one/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Wed, 18 Feb 2026 16:00:55 +0000 /?post_type=article&p=2515929 2515929 Postpartum depression in dads is common – we can now spot and treat it /article/2514484-postpartum-depression-in-dads-is-common-we-can-now-spot-and-treat-it/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Wed, 18 Feb 2026 16:00:20 +0000 /?post_type=article&p=2514484 2514484 Psychedelic reduces depression symptoms after just one dose /article/2515598-psychedelic-reduces-depression-symptoms-after-just-one-dose/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Mon, 16 Feb 2026 16:00:54 +0000 /?post_type=article&p=2515598
Psychedelics may enable the brain to form new connections
wildpixel/Getty Images

A single dose of the psychedelic drug dimethyltryptamine (DMT) had a rapid and sustained effect on depressive symptoms in a small trial.

DMT – a fast-acting and extremely potent psychedelic found in numerous plants across the world – is subject to the strictest international controls, with the United Nations considering it a substance with high abuse potential and no recognised medical use.

But a wave of observational research suggests that DMT, and other psychedelics, could help people with severe mental health conditions, particularly those .

In the latest study, at Imperial College London and his colleagues studied 34 people who had experienced moderate to severe depression for an average of 10 years, and who had unsuccessfully tried at least two conventional medicine- or psychotherapy-based treatments.

Alongside psychotherapeutic support, half of the participants were given a large, 21.5-milligram dose of DMT intravenously over 10 minutes, while the rest received a placebo infusion.

All the participants completed a depression-rating questionnaire at the start of the study. Two weeks after the infusions, the DMT group saw their depression-rating scores go down by 7.4 points more, on average, than the placebo group. This was consistently maintained for three months, and for up to six months for some of the participants.

In another part of the study, all of the participants were free to have a dose of DMT, either as a second dose or, for the placebo group, the first, alongside therapist support. This didn’t significantly improve outcomes beyond the first dose, suggesting that one treatment is sufficient for a lasting effect.

In terms of safety, side effects were mild, with some of the participants reporting temporary anxiety, nausea and pain at the site of infusion.

“We’ve shown that a single DMT experience, lasting only around 25 minutes, can be safe, well-tolerated and associated with meaningful improvements in depression that appear to persist beyond the acute psychedelic state,” says Erritzoe. “What’s promising is how comparable these early signals look to results seen in trials of longer-acting psychedelics such as psilocybin.” A shorter psychedelic experience should reduce treatment costs, he says.

But the nature of taking a psychedelic means people can typically gauge whether or not they are in the placebo group, so the results may reflect both DMT’s effects and the participants’ expectations.

The researchers noted that the intensity of mystical-type experiences that the DMT group reported about 25 minutes after receiving the drug was linked to their degree of therapeutic improvement. “The more someone felt a sense of unity; a deeply positive emotional shift; a change in how they experienced time and space; and something so profound it was hard to put into words, the more benefit they tended to report afterwards,” says team member , also at Imperial.

Although it is unclear exactly how psychedelics like DMT may be beneficial for treating depression, research suggests that taking them provides a temporary window of neuroplasticity, where the brain can form new connections, or that they may dampen inflammation associated with poor mental health.

– a pioneer in psychedelics research – says these results build upon in which the participants were told which drug they were taking. Yet he still stresses the importance of progressing cautiously. “While the DMT experience is briefer than psilocybin and LSD, it can be significantly more disorienting than longer-acting psychedelics and requires careful preparation, monitoring and follow-up.”

Erritzoe and his team say the results should help guide the testing of a modified form of DMT called for anxiety by Helus Pharma. In the meantime, a similar molecule, called 5-MeO-DMT, is at a more advanced testing stage for depression. For instance, in New York mean that the development of its candidate for treatment-resistant depression can be expedited, making US approval likely.

Journal reference:

Nature Medicine

Article amended on 16 February 2026

This article has been changed to correct the dose of DMT the participants received and to clarify who is testing HLP004.

Article amended on 17 February 2026

This article has been changed to correct the dose of DMT the participants received from micrograms to milligrams.

]]>
2515598
Psychiatry has finally found an objective way to spot mental illness /article/2509966-psychiatry-has-finally-found-an-objective-way-to-spot-mental-illness/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Wed, 14 Jan 2026 16:00:14 +0000 /?post_type=article&p=2509966 2509966 Exercise may relieve depression as effectively as antidepressants /article/2510492-exercise-may-relieve-depression-as-effectively-as-antidepressants/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Thu, 08 Jan 2026 01:00:25 +0000 /?post_type=article&p=2510492
Jogging in mist and fog
Exercise can form part of an effective treatment for depression
Neil Lang/Shutterstock

Many of us experience a mood-boost after exercise, and now an updated review has revealed just how powerful it can be. Even light exercise, like walking or gardening, may ease the symptoms of depression as effectively as talking therapies or antidepressants.

“It really reiterates that exercise provides an option for people who have depressive symptoms, and confirms that exercise may be as effective as psychotherapy and antidepressants,” says at the University of Lancashire in the UK.

Prior studies, including a , have found that exercise may ease symptoms of depression as effectively as standard therapies, including antidepressants and cognitive behavioural therapy (CBT), where a therapist helps people change their thoughts, feelings and behaviour.

This has prompted healthcare organisations to recommend regular exercise for managing depression. For instance, the UK’s National Institute for Health and Care Excellence (NICE) recommends weekly aerobic exercise, such as jogging, for 10 weeks – usually in combination with other therapies, which, on their own, don’t benefit everyone.

But since the 2013 review, dozens more trials have been conducted, so the Cochrane Library is now publishing an updated review. “This latest review [almost] doubles the evidence base that was in the previous one,” says Clegg, one of the review authors.

Clegg and his colleagues analysed results from 69 randomised controlled trials involving nearly 5000 adults who were either clinically diagnosed with mild, moderate or severe depression, or who register a score on a depression symptom scale that is generally considered indicative of the condition. First, the researchers focused on 57 of the trials in which participants were randomly assigned either to a group that exercised regularly or to a control group that was offered no treatment or that was placed on a waiting list for treatment.

The trials varied in design, but they usually involved asking participants to exercise on a weekly basis for a few weeks to months, with the style of exercise ranging from low- or moderate-intensity activities such as gardening and brisk walking, respectively, to vigorous activities such as sprinting or playing football. Trials involving yoga or stretching weren’t included as these often involve meditation and breathwork, and the team wanted to focus more on the effects of physical activity alone, says Clegg.

The team found that exercise seems to moderately reduce the severity of depressive symptoms, such as often feeling sad, or losing interest in other people.

“They found a clinically meaningful change – people will feel the difference from that,” says at King’s College London, who wasn’t involved in the review.

Next, the team focused on 10 trials among the 59 that compared exercise to CBT, and five trials in which some participants took antidepressants but there was no exercise component at all. This revealed that, on average, regular exercise worked as well as the two other therapies. “There wasn’t a difference between them,” says at University College London, who wasn’t involved in the study.

By taking a closer look, the team found that light and moderate exercise seem to be more effective than vigorous kinds, which may simply be because they are easier to stick with, says Stubbs. “If you start going hard, then people drop out and stop exercising, and that could be why you don’t see the same effects [as with less strenuous activity],” he says.

How exactly exercise brings its benefits is unclear, but it probably works in several ways, says Stubbs. Group exercise, for instance, can boost people’s social well-being, while learning a new skill can improve self-esteem, both of which can help people to make positive changes in their lives, he says.

Studies have also shown that, during exercise, chemicals released from muscles, called myokines, that is thought to contribute to depressive symptoms, says Stubbs. One particular myokine, called brain-derived neurotrophic factor, also spurs the growth of new brain cells, which could help the brain to rewire itself and break free of negative thought patterns, says Stubbs. In line with this idea, Clegg and his colleagues found that resistance training – which leads to a greater release of myokines versus other forms of exercise – was more effective than aerobic exercise alone, says Stubbs.

Together, the findings support guidelines that recommend exercise for treating depression. However, in all the studies reviewed, participants knew whether they were in a treatment group or control group. This raises the possibility that at least some of the exercise-related improvements could be down to the placebo effect, where people’s expectations lead to an improvement in symptoms, says Hird. What’s more, most of the studies involved relatively small numbers of participants, which makes their conclusions less reliable, she says.

Larger studies are needed to better understand which types of exercise – including those not included in the review – are most beneficial, for whom, and why that is, says Hird. “We don’t really understand who is going to benefit from what at the moment,” she says. For instance, people with more severe kinds of depression may find it harder to get out and exercise, so they may benefit from CBT or antidepressants – both of which the review confirms are as effective as exercise for treating depression. It’s also possible that someone who is in a position to exercise may benefit more from a specific kind of exercise over another depending on the underlying cause of their depression, she says.

Still, the evidence to date consistently shows that exercise brings both mental and physical health benefits, says Stubbs. “Whether it be running, gym, pilates, yoga, these all have various beneficial effects – the most important thing is empowering people to do something they enjoy,” he says.

Journal reference:

Cochrane Library

]]>
2510492
Antidepressants vary widely in their physical side effects /article/2500834-antidepressants-vary-widely-in-their-physical-side-effects/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Tue, 21 Oct 2025 22:30:53 +0000 /?post_type=article&p=2500834
Different people may benefit from some antidepressants over others, depending on their side effects
Mariia Veklenko/Getty Images
Antidepressants vary greatly in the side effects they cause – from weight gain to weight loss and blood pressure changes. This may need to be taken into account when doctors decide which of the many drug options, which can be lifesaving, would be best for each individual. About 1 in 10 people in and take antidepressants for conditions such as depression and anxiety. Withdrawal symptoms may be less common than we thought, but while you are taking these drugs. It just isn’t clear which specific drug causes which kind of side effect. Drilling deeper into the data, at King’s College London and his colleagues analysed results from 151 randomised-controlled trials and 17 US Food and Drug Administration reports. These covered 30 antidepressants whose effectiveness and side effects were compared against placebos over around an eight-week course of treatment for various psychiatric conditions. “The beauty of these studies is that they were all placebo-controlled and randomised, so we can be confident that the differences that we are showing are due to the drug,” says Pillinger. The researchers found that some of the drugs were linked with weight loss and others with weight gain. Maprotiline, for example, was linked to an average weight gain of about 1.8 kilograms, whereas agomelatine was linked to losing about 2.4 kg. The study also showed that the drug fluvoxamine was linked to heart rate slowing by 8 beats per minute (bpm), on average, but nortriptyline increased it by 13 bpm. The latter also cut systolic blood pressure – your blood pressure when your heart is contracting – by between 3 and 7 millimetres of mercury (mmHg), while doxepin pushed it up by almost 5 mmHG, which could have knock-on effects on overall health. “Each 1 mmHg increase in your blood pressure, if you have high blood pressure, increases your risk of a stroke by 1 per cent,” says team member , also at King’s College London.
Other drugs, such as paroxetine, duloxetine, desvenlafaxine and venlafaxine, were associated with increases in cholesterol. Whether these side effects worsen, improve or plateau beyond eight weeks is unclear. Despite observational studies raising concerns that antidepressants affect levels of electrolytes, such as sodium, in blood, which could impact heart rhythms, “our study showed that actually there weren’t any problems at all with sodium”, says Pillinger. Of the last year, about 85 per cent were either . Four of these were found to have a relatively good profile for most of the examined factors, but amitriptyline was seen to increase weight, heart rate and blood pressure, while venlafaxine raised heart rate, blood pressure and cholesterol. “This is very informative for both physicians and patients,” says at epidemiology consulting group Epilytics in Vancouver, Canada. “This data can be put into an app, so, for example, if somebody has high cholesterol or cardiovascular problems, the app can tell the physician which one to avoid. This will give physicians more bandwidth to choose the antidepressant that best fits a patient.” Pillinger says his team is developing a digital tool with a drop-down menu of an antidepressant’s common side effects, so medics can gauge which to avoid, or even which to choose, for example if weight loss would be beneficial. “It’s all about finding the right molecule for the right person and engaging in personalised prescribing,” says Pillinger. But at Stanford University in California says the results may be biased if the team only included studies that showed side effects. Others may have not found side effects, which they didn’t report, meaning this data wasn’t included in the meta-analysis. He also points out that people generally take antidepressants for longer than 8 weeks; sometimes for years. “Very different, long-term studies would be needed to show the presence and relevance of such outcome effects, if any, in the long-term,” says Ioannidis. In response, Pillinger says there is “always the risk of bias” but “we can be relatively confident that we have gathered most of the data that is out there”. He accepts an analysis of longer-term studies is needed, which he says his team is working on, and points out that about 75 per cent of the participants in the existing trials were white. But he thinks the patterns the team spotted will show up in longer-term studies and will probably apply to other groups. Previous studies suggest that some antidepressants, such as venlafaxine, , he says. Weight gain that occurs quickly can also last, he says. “Once you put the weight on, it’s hard to get rid of it.” People on antidepressants who are worried about side effects shouldn’t stop their treatment, though, says Howes, because these medications can be very effective. “This is nuanced; it’s an individual decision, reflecting an individual’s risk profile and the benefits. If they are concerned, this is something that we would recommend that they talk to their doctor about.”
Journal reference:

The Lancet

]]>
2500834
How to nurture the right mindset for living to 100 /article/2495108-how-to-nurture-the-right-mindset-for-living-to-100/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Tue, 16 Sep 2025 15:00:13 +0000 /?post_type=article&p=2495108 2495108 Brain implant lets man ‘experience joy’ for the first time in decades /article/2493065-brain-implant-lets-man-experience-joy-for-the-first-time-in-decades/?utm_campaign=RSS|NSNS&utm_content=depression&utm_medium=RSS&utm_source=NSNS Tue, 19 Aug 2025 17:00:24 +0000 /?post_type=article&p=2493065 2493065